Literature DB >> 29332992

Experiment Design for Early Molecular Events in HIV Infection.

Aditya Jagarapu1, LaMont Cannon1, Ryan Zurakowski1.   

Abstract

The recent introduction of integrase inhibitors to the HIV antiviral repertoire permits us to create in vitro experiments that reliably terminate HIV infection at the point of chromosomal integration. This allows us to isolate the dynamics of a single round of infection, without needing to account for the influence of multiple overlapping rounds of infection. By measuring the various nucleic acid concentrations in a population of infected target cells at multiple time points, we can infer the rates of these molecular events with great accuracy, which allows us to compare the rates between target cells with different functional phenotypes. This information will help in understanding the behavior of the various populations of reservoir cells such as active and quiescent T-cells which maintain HIV infection in treated patients. In this paper, we introduce a family of models of the early molecular events in HIV infection, with either linear dynamics or age-structured delays at each step. We introduce an experimental design metric based on the delta AIC (Akaike Information Criteria) between a model fit for simulated data from a matching model vs a mismatched model, which allows us to determine a candidate experiment design's ability to discriminate between models. Using parameters values drawn from experimentally-derived priors corrupted with appropriate measurement noise, we confirm that a proposed sampling schedule at different time points allows us to consistently discriminate between candidate models.

Entities:  

Year:  2017        PMID: 29332992      PMCID: PMC5761647          DOI: 10.23919/ACC.2017.7962941

Source DB:  PubMed          Journal:  Proc Am Control Conf        ISSN: 0743-1619


  21 in total

1.  A Bayesian approach to parameter estimation in HIV dynamical models.

Authors:  H Putter; S H Heisterkamp; J M A Lange; F de Wolf
Journal:  Stat Med       Date:  2002-08-15       Impact factor: 2.373

2.  A benchmark for methods in reverse engineering and model discrimination: problem formulation and solutions.

Authors:  Andreas Kremling; Sophia Fischer; Kapil Gadkar; Francis J Doyle; Thomas Sauter; Eric Bullinger; Frank Allgöwer; Ernst D Gilles
Journal:  Genome Res       Date:  2004-09       Impact factor: 9.043

Review 3.  HIV-1 reverse transcription.

Authors:  Wei-Shau Hu; Stephen H Hughes
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

4.  Modeling uncertainty in single-copy assays for HIV.

Authors:  Rutao Luo; Michael J Piovoso; Ryan Zurakowski
Journal:  J Clin Microbiol       Date:  2012-07-25       Impact factor: 5.948

Review 5.  Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication.

Authors:  Frank Maldarelli
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

6.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Authors:  M R Furtado; D S Callaway; J P Phair; K J Kunstman; J L Stanton; C A Macken; A S Perelson; S M Wolinsky
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

7.  On validation and invalidation of biological models.

Authors:  James Anderson; Antonis Papachristodoulou
Journal:  BMC Bioinformatics       Date:  2009-05-07       Impact factor: 3.169

8.  Discriminating between rival biochemical network models: three approaches to optimal experiment design.

Authors:  Bence Mélykúti; Elias August; Antonis Papachristodoulou; Hana El-Samad
Journal:  BMC Syst Biol       Date:  2010-04-01

9.  Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity.

Authors:  D F Purcell; M A Martin
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

10.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Authors:  M E Sharkey; I Teo; T Greenough; N Sharova; K Luzuriaga; J L Sullivan; R P Bucy; L G Kostrikis; A Haase; C Veryard; R E Davaro; S H Cheeseman; J S Daly; C Bova; R T Ellison; B Mady; K K Lai; G Moyle; M Nelson; B Gazzard; S Shaunak; M Stevenson
Journal:  Nat Med       Date:  2000-01       Impact factor: 87.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.